BioMedicine
Volume 10

Issue 3

Article 5

2020

Evaluation of Sodium Valproate Low Dose Efficacy in Radicular
Pain Management and It’s Relation with Pharmacokinetics
Parameters

Follow this and additional works at: https://www.biomedicinej.com/biomedicine
Part of the Other Pharmacy and Pharmaceutical Sciences Commons, and the Rheumatology
Commons

This work is licensed under a Creative Commons Attribution 4.0 License.
Recommended Citation
Ghasemian, Mona; Owlia, Mohammad Bagher; Mosaddegh, Mohammad Hossein; Nakhaie nejad, Masoud;
and Sohrevardi, Seyed Mojtaba (2020) "Evaluation of Sodium Valproate Low Dose Efficacy in Radicular
Pain Management and It’s Relation with Pharmacokinetics Parameters," BioMedicine: Vol. 10 : Iss. 3 ,
Article 5.
DOI: 10.37796/2211-8039.1039

This Original Articles is brought to you for free and open access by BioMedicine. It has been accepted for inclusion
in BioMedicine by an authorized editor of BioMedicine.

Evaluation of Sodium Valproate Low Dose Efficacy in Radicular Pain
Management and It’s Relation with Pharmacokinetics Parameters
Cover Page Footnote
we greatly appreciate Arefeh Dehghani Tafti (statistics consultant) for her useful comments.

This original articles is available in BioMedicine: https://www.biomedicinej.com/biomedicine/vol10/iss3/5

Mona Ghasemian a, Mohammad Bagher Owlia b, Mohammad Hossein Mosaddegh c,
Masoud Nakhaie nejad d, Seyed Mojtaba Sohrevardi a,*
a

Department of Clinical Pharmacy, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
Department of Internal Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
c
Department of Toxicology, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
d
Department of Pharmaceutical Sciences, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
b

Abstract
Background: Radiculopathy due to lumbar or cervical disc disease is the most common chronic neuropathic pain in
adults. The aim of present study was evaluation of low dose of sodium valproate (VPA) on radicular pain and determining VPA pharmacokinetics.
Materials and Methods: In this double blind randomized placebo control clinical study, 80 patients with established
lumbar or cervical radicular pain, have been randomly allocated into two study groups: 40 have received sodium valproate 200 mg/day and Celecoxib 100 mg/day and acetaminophen 500 mg PRN as rescue medication, and second group
has received placebo, Celecoxib and acetaminophen. Quantitative assessment of pain was done by visual analogue scale
(VAS) prior to perform the intervention and after ten days (treatment duration). Blood sample has been taken for
determining mean through concentration after ﬁve half-lives. Evaluation of plasma concentration of VPA and that of
efﬁcacy on pain score relationship by comparing VAS before and after the therapy was done.
Results: Group A and B have demonstrated signiﬁcant alleviation in mean VAS score; ¡21.97 ± 25.41, ¡14.39 ± 23.03
respectively (P < 0.001). The mean plasma concentration of VPA in group A was: 26.9 ± 13.5 mg/L. Moreover, no signiﬁcant correlation was seen between pain score with age, gender, and weight (p > 0.05).
Conclusion: Low dose of sodium valproate especially together with NSAIDs demonstrated good efﬁcacy in lumbar and
cervical radicular pain management.
Keywords: Low dose, Pharmacokinetic, Radicular pain, Sodium Valproate, Anti-convulsant

1. Introduction

R

adicular pain is the main manifestation of
radiculopathy that lancinating and traveling
on a narrow band which it maybe repetitive
episode or paroxysmal. The main cause of this form
of pain is ectopic activation of ischemic damaged
nerve roots or inﬂamed dorsal root ganglion [1, 2].
The chief complain of cervical and lumbar radicular pain is radiated knife like shooting pain in
shoulder to arm and leg to foot respectively [3, 4].
Cervical and lumbar radicular pain is often

correlated with neurologic symptoms comprise of
numbness, lacks of sensitivity reﬂexes and motor
weakness called radiculopathy [4]. Although lumbar radicular pain owing to damaged disc is at least
20 times more common than other neuropathic
pains with 4.5% prevalence in adults older than
30 years old, there are no analgesic dose-control
trials in this disease [5]. It is essential to consider
that other neuropathic syndrome such as diabetic
and post-herpetic neuralgia have different site and
pathology and generalizing those research outcomes to radiculopathy seems to be inappropriate
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available evidence for that of minimum effective
dose is not enough and sufﬁcient. The main goals of
this present study are evaluation of effectiveness of
low dose of VPA in Iranian radicular pain patients
and correlation of trough concentration of VPA
with visual analog scale (VAS).

2. Material and methods

Fig. 1. Consort Diagram.

[5]. Untreated radiculopathy can lead to disablement and impose a huge economic burden on individuals and society. Through various treatments
have been applied, anti-convulsant drugs have
demonstrated satisfactory results to pain relieving
in radicular pain patients. Sodium valproate (VPA)
is an anti-convulsant medicine which has proved to
be efﬁcient in migraine prophylaxis and trigeminal
neuralgia, diabetic neuropathy [6, 7] and chronic
central pain after spinal cord injury [8]. The main
mechanism of action has been proposed for valproate is prevention in degradation and neuronal
uptake of Y-amino butyric acid (GABA) as an
inhibitory neurotransmitter in central nervous
system [9]. In recent studies the maximum possible
dose of sodium valproate has been dispensed for
neuropathic pain relieving [6-8]. Though the

The present double-blind randomized placebocontrolled study was conducted in 80 patients (35
male, 45 female) who have suffered from cervical
and or lumbar radicular pain (Fig. 1). 20-70 years old
subjects without any certain medical complication
such as gestation, heart failure, liver and or kidney
disease had been enrolled for the trial, likewise
patients who have taken non-steroidal anti-inﬂammatory drugs, anti-convulsants for radicular pain
relief or other medical reasons and any drugs which
had had direct or indirect impress on patients subjective pain insight (SSRI or TCA and other antidepressants) were excluded or if it was possible the
patients were asked to stop drugs at least one week
before study.
Diagnosis was based on history of the symptoms
and physical examination, straight leg raise test
have been used to recognize a lumbar radiculopathy
by rheumatologist.
The selected Patients had been allowed time to
ask questions before written informed consent was
taken.
All patients were randomly divided into 2 groups,
randomization was done by the use of random
numbers table, treatment plan of group A
comprised of sodium valproate 200 mg/day, Celecoxib 200 mg/day and acetaminophen 500 mg PRN
(acetaminophen, up to 2000 mg/day was allowed as
the rescue medication), group B or control group's
treatment plan contained placebo once a day, Celecoxib 200 mg/day and acetaminophen 500 mg PRN,
duration of treatment was ten days, meanwhile all
patients were emphasized that Valproate must be
administered on 12 AM before meal and Celecoxib
must be administered at night after dinner, except
for treatment with sodium valproate, target therapy
groups and control group were similar in all respects. The placebo tablets were identical in shape
and color with that of valproate sodium tablets. All
patients, who had been enrolled for group A, took
valproate tablets in the same batch number from the
same manufacturer company. All patients were
monitored for adverse events (gastrointestinal disorders, allergic reaction, and somnolence and…)
during the course of treatment. Each patient was
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Table 1. Distribution of males and females in terms of parameters.
Group

parameters
Age

Weight (Kg)

VAS 1 (mm)

VAS 2 (mm)

A

44.8 ± 14.9

71.2 ± 12.1

58.5 ± 24.4

36.6 ± 25.8

B

48.5 ± 12.9

71.6 ± 11.4

49.0 ± 21.2

34.6 ± 23.5

P value

NSc

NS

NS

NS

a
b
c

Pain area
Ca

Lb

L-C

12
(31.6%)
8
(21.1%)
NS

24
(63.2%)
29
(76.3%)

2
(5.3%)
1
(2.6%)

Cervical.
Lumbar.
Not signiﬁcant.

rated his/her pain intensity on the visual analog
scale (VAS) from 0-100 (0 ¼ no pain, 100 ¼ worst
pain imaginable) before beginning and after the end
of intervention (VAS assessment occurred at baseline and day ten). The number of consuming acetaminophens as a rescue medication was recorded in
a personal diary during ten days by each subjects
and was documented in individuals relevant information ﬁle after the end of therapy by the member
of research team. After collecting data, all of them
were evaluated by blinded statistician and then the
outcomes were decoded and divided the same into
target therapy group (A), group (B) and then were
compared to each other.
Inclusion criteria: 1. Diagnosis of lumbar or cervical radicular by the rheumatologist. 2. Age between 20 and 70 years. 3. No possibility of health
risk or confounding by other diseases, e.g., pregnancy, hepatic or kidney disorders, congestive heart
failure. 4. Normal liver function 5. Patients hadn't
used valproate sodium or if they had been using,
they must remember pain intensity before using
valproate sodium and can compare with current
pain intensity. 6. Weight between 50 and 90 kg.
Exclusion criteria: 1. Intolerance to sodium valproate side effects. 2. Allergic history to VPA or
NSAIDs. 3. Patients would be forced to administered medicines that change protein binding or
clearance of valproate sodium. 3. Patients would be
given diseases that affect the results of study.
Gas chromatography method.

break time (in order to complete acidiﬁcation process) deionized water was added to ten ml gradually, this samples were stored in 2-8 c following
3 min mixing until analyzed.
2.2. Spiking solutions and calibration curve
The serial dilution of spiking solutions were made
up by adding the different amounts of the stock
solution (10 mg/ml) to 0.5 ml drug free serum,
deproteinating and the rest of process have been
done according what was mentioned in sample
preparation method, diluting with deionized water
up to ten ml in order to obtain different concentrations from 2-100 mg/ml (2, 5, 10, 20, 40, 50, 100) was
performed. All spiking samples were analyzed by
gas chromatography/ﬂame ionization detector (GC/
FID) in the same constant thermal ramping with the
unknown samples, calibration curve and linear
regression were performed then the Y-intercept and
the slope of plotted curve were calculated and
replaced in linear equation.
2.3. Extraction method
Analyte have been extracted by solid phase micro
extraction (SPME) method. For creating a partitioning between the sample matrix and the ﬁbre

2.1. Sample preparation
All blood samples were stored in 20 C till
analyzed. 0.5 ml of each serum was separated and
four drops perchloric acid 60% was added in order
to protein precipitation and achievement to desire
PH (1), this was followed by ﬁve min shaking to
complete deproteination, after centrifugation at
3000 rpm for ten min the supernatant ﬂuid was
transferred to a ten ml volumetric ﬂask, after 20 min

Fig. 2. Calibration curve.
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Group

Conc. (mg/L)

Ke(1/h)

AUC

Vd (L/kg)

Cltrue (ml/kg/h)

Clpopulation (ml/kg/h)

t1/2 (h)

A

26.9 ± 13.53

0.02 ± 0.01

15.54 ± 7.95

9.73 ± 1.59

0.26 ± 0.09

0.55 ± 0.09

29.65 ± 14.31

coating the needle of SPME set was passed through
the septum which sealed sample vial and the polyacrylate ﬁbre was entered to headspace above the
sample in this meantime the glass vial of sample
was heated and stirred by the hotplate Labtron
model L-50; magnet stirrer speed was set on point
one and temperature on 60 C. sample extraction
and desorption time were 20 and ﬁve min
respectively.

3. Results
All groups were similar in demographic features
like mean age, mean weight, and primary and secondary pain scores as summarized in Table 1. Distribution of males and females was identical among
the groups. The mean age of patients in group B was
a bit greater than the other group. The patients with
radicular cervical and lumbar pain showed a similar
scattering pattern. The difference in the patients’
primary pain scores was not signiﬁcant among the
two groups. Two patients in each of Group A and
Group B did not present to laboratory for follow-up
because they did not consume the drugs due to their
ignorance towards treatment. The area under the
curve (AUC) was converted to concentration
through calibration curve line equation obtained
from Fig. 2 where Y represents plasma concentration and X is the area under curve. According to
what was explained under “Methodology”, the parameters of trough concentration (Conc), elimination constant (Ke), true clearance (true Cl), volume
distribution (Vd), and true half-life were calculated
for each patient as given in Table 2. The population
elimination constant was estimated by considering
8 mg/kg/h clearance and population distribution
volume 0.14 L/Kg using formula (1) which is constant for all patients.
Formula 1:
 
 
lit
1
Cl
¼ VdðlitÞke
ð1Þ
hr
hr

Ke population (1/h) ¼ 0.057.
Similarly, the population half-life for valproate
sodium was calculated using formula (2), a parameter which is again constant for all patients.
Formula 2:
t 1 2 ðhÞ ¼
=
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Table 2. Pharmacokinetic parameters in group A.

0:693
 
ke 1=h

ð2Þ

T1/2 (h) ¼ 12.15.
The differences in the primary and secondary
pain scores between two groups were compared.
Also, the mean number of patients’ consumed
Acetaminophen tablets during ten days of treatment
period was estimated and compared for the two
groups. Patients in Group B took an average number of 5.08 rescue medication which was a bit
greater compared to Group A (3.08) though it was
not signiﬁcant (p ¼ 0.597). Also, no signiﬁcant difference was observed between the difference of pain
scores of groups after treatment and the number of
Acetaminophen taken by Group A and Group B.
Finally, the correlation between age, gender, and
weight with pain score difference was investigated
indicating no signiﬁcant correlation.

4. Discussion
Sodium valproate is an anticonvulsant drug [1028] widely used in treating various neuropathic
pains induced by cancer, diabetes, or irritation of
trigeminal nerve and also treating various headaches such as migraneous headaches [6-8, 29-32].
None of the existing studies have investigated the
efﬁciency of valproate sodium in relieving radicular
pains. Since the pathophysiological nature of these
pains is different from that of other mentioned
neuropathies, the results and ﬁndings of these
studies could not be safely generalized to this type
of pain and to this group of patients with this
problem [5]. An important point to be kept in mind
by physicians is the administration of the minimum

Table 3. Comparison of various pain scores in groups.
Group

VAS 1
(mm)

VAS 2
(mm)

Mean (mm)
VAS2-VAS1

P value

A
B

58.5 ± 24.4
49.0 ± 21.2

36.6 ± 25.8
34.6 ± 23.5

-21.9±25.4
-14.3±23.0

<0.001
<0.001
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effective dose which both satisﬁes patients and induces the least amount of complications in them.
The incidence of a common but unpleasant
complication such as gastrointestinal disturbances
may result in patient dissatisfaction and cessation of
their compliance with the physicians and required
follow-up. The prescribed daily dose of VPA in all
clinical trials conducted so far has been in the range
of 1800-2400 mg/day [8]. The consumption of this
amount of VPA per day would undoubtedly lead to
many gastrointestinal and hepatic complications.
In this study, the group receiving VPA and Celecoxib simultaneously reported a maximum reduction of 79 units and a minimum reduction of 35 units
in pain score (Table 3). Also, the group receiving
placebo and Celecoxib simultaneously reported a
maximum reduction of 74 units and a minimum
reduction of 28 units in pain score. The P-values
obtained indicate a signiﬁcant difference between
the primary and secondary pain scores in Groups A
and B meaning that there has been a signiﬁcant
improvement. A cross-comparison of pain score
reduction among the two groups suggested no signiﬁcant difference. However, the fact that the pain
showed an acceptable response to analgesics and
anti-inﬂammatory drugs during initial days of
treatment can't be used as a basis for our judgment
on the long run. Consequently, increasing the
treatment length and longer patient follow-ups in
future research can result in better and more valid
results. Moreover, lack of a separate control group
to receive placebo alone due to ethical codes of
research prevented us from eliminating the psychological effect of drug consumption on our results. This ﬁnding shows separately the comparison
of the pain scores before and after intervention in
the two groups. As the plasma concentration of the
drug alone does not indicate its efﬁciency in controlling convulsions [33], it is neither an appropriate
index for judgments on controlling pain in patients.
Nevertheless, this rate of pain reduction obtained
with low doses of valproate sodium may be
rendered as an improvement in pain reduction for
patients who had occasionally reported severe
pains.
In the study by Drews et al. (1994), 1200-2400 mg/
day valproate sodium was administered to 20 spinal
injury patients on the basis of their response to
treatment (the mean plasma concentration of the
patients was 614 mmol/L). The response to treatment
and pain reduction in patients were investigated by
McGill pain questionnaire. No statistically signiﬁcant difference was found at the end of the treatment period between the patients who received this
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medicine and those who received placebo despite a
%33 reduction in pain [8].
Kochar et al., assessed the role of sodium valproate for treating of pain in diabetic neuropathy. In
this regard, they assessed pain via Visual Analogue
score McGill Questionnaire at beginning, after 1 and
3 months of study and observed that sodium valproate provides signiﬁcant improvement in
reducing pain in patients with diabetic neuropathy,
which was consistent with our study [34]. Hardy
et al., also observed the efﬁcacy of sodium valproate
in neuropathic pain of cancer patients [35]. Hering
et al., assessed the role of sodium valproate in the
treatment of headache. In this regard, they administered the dose 600 and 2000 mg/day for patients
and reported that sodium valproate seems to be an
efﬁcacious drug for treatment of headache [36]. This
ﬁnding was also consistent with our study. Cuter
et al., estimated the effect of valproate in pain of
animal models and reported that the effect of valproate is performed via binding to GABA receptor
in animal models [37]. But, Gill et al., evaluated the
role of Valproic acid for neuropathic pain during
12 weeks and reported that no adequate evidence
was seen to use the Valproic acid [38]. It seems that
more research should be done in this regard,
especially Valproic acid and radicular pain.
In addition, clinical observations on our population race demonstrated that for some medicines, the
doses administered to patients on the basis of
medical references exceeded the needs of the patients. The clinical study has been done on Iranian
race indicated that Iranian patients have different
pharmacokinetic parameters of Phenytoin from the
reported mean values in other population, according to this study; Iranian population demonstrated
higher Michaelis-Menten constant (Km) and lower
maximum rate of metabolism (Vm) than other races
and ignoring this issue could lead to increasing risk
of adverse reactions. E. Salehifar and et al claimed
that our population may have a lower metabolic
capacity for phenytoin metabolism and lower
expression of CYP2C9 and CYP2C19 that these data
could help the specialists to optimization and

Table 4. Comparison of true and population pharmacokinetic parameters in group A.
P value
Group A

CLtrue
CLpopulation
T1/2true
T1/2 population
Ketrue
Ke population

0.26 ± 0.09
0.55 ± 0.09
29.65 ± 14.31
12.15
0.027 ± 0.01
0.057

<0.001
<0.001
<0.001
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individualize antiepileptic therapy [39]. CYP-mediated biotransformation is one of the route of VPA
metabolism and CYP2C9 play the pivotal role in that
[40]. Thus according to the research has been done
on 179 Asian patients for investigating inﬂuence of
cytochrome oxidase polymorphisms on the steadystate standardized plasma VPA concentrations;
subjects with low expression of CYP2C9 alleles had
higher mean plasma valproic acid concentrations in
comparison to those without, because these categories of metabolizing enzymes lead VPA to inactive
metabolites such as 4-OH-VPA and 5-OH-VPA [41].
Another study conducted in Iran on the effects of
Daclizumab in kidney transplant patients approved
the efﬁcacy of low dose (two doses) of the drug
without noticeable complications while Daclizumab
is routinely used with higher doses (ﬁve doses) to
prevent transplant rejection [42]. This study provides us with an evidence of pharmacodynamic
differences of drugs in the Iranian population. Since
speed of metabolism and subsequently, inactivation
of drugs plays a signiﬁcant role in determining the
effective required dose, hence, a revision of the
current doses of some drugs is rendered as an
important issue in drug therapy in various races of
patients.
Also, in surveying the number of Acetaminophen
tablets taken by each group, it was observed that,
patients in Group A had taken 3.08 ± 5.16 tablets on
average while those in Group B had consumed
5.08 ± 8.07 Acetaminophen tablets on average being
greater than Group A. The two groups under study
were not signiﬁcantly different in this parameter (p
value ¼ 0.597). It should be pointed out that during
the orientation session when the procedures of
drug administration were explained to each patients, it was observed that the majority of patients
had a negative attitude towards Acetaminophen
consumption showing no inclination for taking this
tablet even in the presence of pain. This can justify
the low mean of Acetaminophen consumption in
the Placebo Group and even the intervention
group. The pharmacokinetic parameters obtained
from the intervention group receiving VPA are
signiﬁcantly different from those obtained for
population studies (Table 4). These statistical data
demonstrated that drug clearance of our patients is
lower than that of in population studies, also the
similar results have been reported in Sohrevardi
SM et al [42].
This indicates that our study population demands
its own pharmacodynamic and pharmacokinetic
investigations and that making judgments on the
basis of studies on other populations would be
misleading and inaccurate. The half-life obtained
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from kinetic estimations for the consumption of the
drug once per day was averagely 29.6 h for its
simultaneous consumption with Celecoxib (Table 2),
while the half-life reported for this drug in adults in
pharmacopoeia is 5-20 h [18, 43].
A wide ﬂuctuation was observed in trough concentration among the patients in Group A so that an
SD of 13.53 was obtained for this group. This could
be probably attributed to the effect of Celecoxib in
the metabolism and clearance of drug which varies
from individual to individual (Table 2). An increased
drug clearance may also be used as the basis for
judgments on drug elimination.
Chronic pains such as pains of neuropathic nature may have several simultaneous causes, all of
which are able to play a role in the course of patient's healing. Consequently, these pains may be
considered to be multifactorial among which are
anxiety disorders, depression, insomnia, and low
energy levels or lethargies. Hence, chronic pain
control is not possible just with eliminating the
inducing factor, rather it demands some multilateral approach [44]. Moreover, the effects of environmental factors, nutritional habits, life style, age,
and health level on individuals' responses to drugs
could not be ignored since they alter the results of
kinetic studies. On the other hand, the genetics of
individuals also affects the kinetics and dynamics of
drugs as metabolizing enzymes of drugs, pharmaceutical receptors, protein transmitters of drugs,
ionic channels, etc are controlled by genes. Thus,
the effects of genetics, race, and life environment
are of utmost importance in the incidence of
pharmacological complications and treatment responses [45].

5. Conclusion
On the basis of the interventions conducted in this
study, we may conclude that:
1. Low doses of valproate sodium speciﬁcally along with
NSAIDs demonstrate very pronounced therapeutic effects on
reduction and even removal of radicular chronic pains.
2. The half-life, elimination constant and true clearance of drug
for each patient was signiﬁcantly different from the equivalent parameters obtained from population studies (Table 4).
3. Lower true clearance in our patients in comparison of population studies results proved that not only drug efﬁcacy
assessment but also therapeutic drug monitoring (TDM) and
drug plasma concentration determination is necessary for
prescription.

Hence, it is recommended that supplementary
studies on pharmacokinetics and their NSAIDs interactions be carried out with a focus on eliminated
metabolites of drugs.
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